Gilead Sciences, Inc. $GILD Shares Sold by Verity Asset Management Inc.

Verity Asset Management Inc. lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 51.3% in the 2nd quarter, Holdings Channel reports. The fund owned 11,794 shares of the biopharmaceutical company’s stock after selling 12,446 shares during the period. Verity Asset Management Inc.’s holdings in Gilead Sciences were worth $1,308,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Gilead Sciences by 12.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock worth $1,541,302,000 after buying an additional 1,520,809 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at approximately $620,415,000. Finally, Nordea Investment Management AB boosted its stake in shares of Gilead Sciences by 39.8% in the second quarter. Nordea Investment Management AB now owns 3,956,933 shares of the biopharmaceutical company’s stock valued at $436,648,000 after buying an additional 1,126,886 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares in the company, valued at $66,013,726.98. This represents a 1.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 71,500 shares of company stock worth $8,336,040 in the last ninety days. Insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on GILD. TD Cowen increased their price objective on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research note on Friday. Citigroup raised their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. Wolfe Research boosted their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, October 23rd. Finally, Rothschild & Co Redburn increased their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $123.87.

Gilead Sciences Trading Up 1.1%

NASDAQ:GILD opened at $119.79 on Monday. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $124.61. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The stock has a fifty day simple moving average of $115.66 and a 200-day simple moving average of $111.66. The company has a market capitalization of $148.64 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.